Further, Boston Scientific’s performance has been mixed over the past year, underperforming both ABT and MDT, while still holding up better than the industry and the sector. Like several other MedTech ...
Boston Scientific (BSX) has quietly outperformed many medtech peers this year, and with the stock hovering near 96 dollars after a modest pullback, investors are asking whether this long term ...
Coloplast (CLPBY) faces operational challenges, with four consecutive top-line misses and reduced growth expectations, but retains a strong core franchise. CLPBY's CEO search remains unresolved, and ...
31 Analysts Assess Ionis Pharmaceuticals: What You Need To Know 4 Analysts Assess Moderna: What You Need To Know The Analyst Verdict: Regenxbio In The Eyes Of 7 Experts 7 Analysts Assess Regenxbio: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback